Document is current
Any future updates will be listed below
-
Authors
Chu, Yu-Yi
Chen, Mei-Kuang https://orcid.org/0000-0001-8027-8990
Wei, Yongkun
Lee, Heng-Huan https://orcid.org/0000-0002-7813-1292
Xia, Weiya
Wang, Ying-Nai https://orcid.org/0000-0002-5275-6729
Yam, Clinton
Hsu, Jennifer L.
Wang, Hung-Ling
Chang, Wei-Chao
Yamaguchi, Hirohito
Jiang, Zhou https://orcid.org/0000-0003-4247-2949
Liu, Chunxiao
Li, Ching-Fei
Nie, Lei
Chan, Li-Chuan
Gao, Yuan https://orcid.org/0000-0003-2224-5538
Wang, Shao-Chun https://orcid.org/0000-0002-5477-1682
Liu, Jinsong https://orcid.org/0000-0002-3239-6658
Westin, Shannon N. https://orcid.org/0000-0002-1922-0156
Lee, Sanghoon
Sood, Anil K. https://orcid.org/0000-0003-4242-1762
Yang, Liuqing https://orcid.org/0000-0002-6518-474X
Hortobagyi, Gabriel N. https://orcid.org/0000-0002-4873-4412
Yu, Dihua https://orcid.org/0000-0001-6231-9381
Hung, Mien-Chie https://orcid.org/0000-0003-4317-4740
- License Information
-
More Information
Article History
Received: 12 April 2021
Accepted: 24 August 2022
First Online: 17 October 2022
Competing interests
: Overcoming PARP inhibitor resistance through the combination of ALK inhibitors and PARP inhibitors, as well as using the ALK–p-Tyr19-CDK9 complex to induce PARP inhibitor resistance in the present study, is covered in the provisional patent UTSC.P1450US.P1. This provisional patent entitled ‘Combinatorial Therapy Targeting PARP1 and RTK’ was invented by M.-C.H., M.-K.C. and Y.-Y.C. and filed by the University of Texas. A.K.S. declares consulting (Merck, Kiyatec), research support (MTrap) and being a shareholder (BioPath). All other authors declare no competing interests.
